Drug Profile
Research programme: Adrenoleukodystrophy gene therapy - Beacon Therapeutics
Latest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Applied Genetic Technologies Corporation
- Developer Beacon Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Adrenoleucodystrophy
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Adrenoleucodystrophy in USA
- 13 May 2020 Preclinical development is ongoing for Adrenoleucodystrophy in USA
- 12 Dec 2018 Applied Genetic Technologies Corporation and Biogen terminate to collaboration effective from March 2019